The market has been high on Onconova Therapeutics Inc (ONTX) stock recently. ONTX gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With ONTX Stock Today?
Onconova Therapeutics Inc (ONTX) stock has gained 28% while the S&P 500 is lower by -0.84% as of 1:28 PM on Friday, Sep 18. ONTX has gained $0.07 from the previous closing price of $0.25 on volume of 81,418,000 shares. Over the past year the S&P 500 has risen 11.65% while ONTX is lower by -81.82%. ONTX lost -$0.97 per share in the over the last 12 months.
To see the top 5 stocks in the Biotechnology industry click here.
More About Onconova Therapeutics Inc
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks signaling by targeting RAS effeccellular tor pathways.
Click Here to get the full Stock Score Report on Onconova Therapeutics Inc (ONTX) Stock.
